Fig. 1
From: Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease
Decreased Crohn’s disease risk for subjects carrying R130Q. A PheWAS analysis was performed on the 23andMe database and evaluated the effect of the R130Q IL-13 variant across a select panel of immunological diseases. Associations between the R130Q IL-13 variant and the immunological diseases are represented as the odds ratios per increase in IL-13 (R130Q) allele number (center of solid square), the number of cases (area of the square), and 95% confidence intervals (extended lines) on a forest plot. The association test p-value reported was computed using a likelihood ratio test
